Dianthus banks $121M for engineered complement mAbs

An initiative by two investment firms to create a more patient-friendly alternative to existing complement therapeutics has led to a $100 million series A round for Dianthus as it advances a mAb nearing the clinic.

The newly-launched company is developing DNTH103, an antibody selective for the active form of C1S that has extended half-life properties. The molecule could compete with Enjaymo sutimlimab-jome from Sanofi (Euronext:SAN; NASDAQ:SNY), which FDA approved in February to reduce the need for red blood cell transfusions in patients with cold agglutinin disease...